New Developments in Prokinetic Therapy for Gastric Motility Disorders
Open accessThe DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
Prokinetic agents amplify and coordinate the gastrointestinal muscular contractions to facilitate the transit of intra-luminal content. Following the institution of dietary recommendations, prokinetics are the first medications whose goal is to improve gastric emptying and relieve symptoms of gastroparesis. The recommended use of metoclopramide, the only currently approved medication for gastroparesis in the United States, is for a duration of less than 3 months, due to the risk of reversible or irreversible extrapyramidal tremors. Domperidone, a dopamine D2 receptor antagonist, is available for prescription through the FDA’s program for Expanded Access to Investigational Drugs. Macrolides are used off label and are associated with tachyphylaxis and variable duration of efficacy. Aprepitant relieves some symptoms of gastroparesis. There are newer agents in the pipeline targeting diverse gastric (fundic, antral and pyloric) motor functions, including novel serotonergic 5-HT 4 agonists, dopaminergic D 2/3 antagonists, neurokinin NK 1 antagonists, and ghrelin agonist. Novel targets with potential to improve gastric motor functions include the pylorus, macrophage/inflammatory function, oxidative stress, and neurogenesis. In the current review, we discuss the use of pharmacological approaches with potential to enhance motor functions in the management of gastroparesis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Clinical Guideline: Management of Gastroparesis
Camilleri, M., Parkman, H. P., Shafi, M. A., Abell, T. L., & Gerson, L. (2013) · American Journal of Gastroenterology · doi:10.1038/ajg.2012.373 · Cited by 1,149
Self-citationPyloric dysfunction in diabetics with recurrent nausea and vomiting
Mearin, F., Camilleri, M., & Malagelada, J.-R. (1986) · Gastroenterology · doi:10.1016/0016-5085(86)90262-3 · Cited by 415 · cited 1×
“In addition, among patients with gastroparesis, a subset of those with antral hypomotility also has evidence of pylorospasm (Mearin et al., 1986).”
BackgroundSelf-citationTack, J., Camilleri, M., Chang, L., Chey, W. D., Galligan, J. J., Lacy, B. E., Müller‐Lissner, S., Quigley, E. M. M., Schuurkes, J., De Maeyer, J. H., et al. (2012) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2012.05011.x · Cited by 286
Self-citationWatkins, C. C., Sawa, A., Jaffrey, S., Blackshaw, S., Barrow, R. K., Snyder, S. H., & Ferris, C. D. (2000) · Journal of Clinical Investigation · doi:10.1172/jci8273 · Cited by 268 · cited 1×
“the use of sildenafil (Watkins et al., 2000), a phosphodiesterase-5 inhibitor which mimics the effect of nitric oxide by increasing intracellular cGMP.”
BackgroundChoi, K. M., Gibbons, S. J., Nguyen, T. V., Stoltz, G. J., Lurken, M. S., Ordog, T., Szurszewski, J. H., & Farrugia, G. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.09.003 · Cited by 239 · cited 1×
“Damage to the pacemaker cells may occur because of depletion of antiinflammatory resident M2 macrophages expressing heme oxygenase-1 (HO1), allowing oxidative stress to damage the pacemaker cells or enteric nerves, as evidenced from animal models of gastroparesis (Choi et al., 2008; Cipriani et al., 2018).”
BackgroundSzarka, L. A., Camilleri, M., Vella, A., Burton, D., Baxter, K., Simonson, J., & Zinsmeister, A. R. (2008) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2008.01.009 · Cited by 209
Self-citationPrucalopride in Gastroparesis: A Randomized Placebo-Controlled Crossover Study
Carbone, F., Van den Houte, K., Clevers, E., Andrews, C. N., Papathanasopoulos, A., Holvoet, L., Van Oudenhove, L., Caenepeel, P., Arts, J., Vanuytsel, T., et al. (2019) · American Journal of Gastroenterology · doi:10.14309/ajg.0000000000000304 · Cited by 206
Pasricha, P. J., Yates, K. P., Sarosiek, I., McCallum, R. W., Abell, T. L., Koch, K. L., Nguyen, L. A. B., Snape, W. J., Hasler, W. L., Clarke, J. O., et al. (2018) · Gastroenterology · doi:10.1053/j.gastro.2017.08.033 · Cited by 143 · cited 3×
“Moreover, in a placebo-controlled trial, the NK1 receptor antagonist, aprepitant, improved multiple symptoms of gastroparesis including nausea (Pasricha et al., 2018).”
BackgroundActions and therapeutic pathways of ghrelin for gastrointestinal disorders
Camilleri, M., Papathanasopoulos, A., & Odunsi, S. T. (2009) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2009.72 · Cited by 115
Self-citationGrover, M., Bernard, C. E., Pasricha, P. J., Parkman, H. P., Gibbons, S. J., Tonascia, J., Koch, K. L., McCallum, R. W., Sarosiek, I., Hasler, W. L., et al. (2017) · Neurogastroenterology & Motility · doi:10.1111/nmo.13018 · Cited by 98 · cited 1×
“…macrophages have been reported in some studies in patients with idiopathic or diabetic gastroparesis (Grover et al., 2011; Grover et al., 2012; Grover et al., 2017), though the ICC results were not confirmed in patients with idiopathic gastroparesis (Bernard et al., 2014; Herring et al.,…”
ResultChange in populations of macrophages promotes development of delayed gastric emptying in mice
Cipriani, G., Gibbons, S. J., Miller, K. E., Yang, D. S., Terhaar, M. L., Eisenman, S. T., Ördög, T., Linden, D. R., Gajdos, G. B., Szurszewski, J. H., et al. (2018) · Gastroenterology · doi:10.1053/j.gastro.2018.02.027 · Cited by 88 · cited 4×
“Gastroparesis may also result from abnormal function of enteric mechanisms which may be targeted by macrophage-based immune dysregulation, as demonstrated in diabetic mice with delayed gastric emptying (Cipriani et al., 2018).”
BackgroundInfluentialChedid, V., Brandler, J., Vijayvargiya, P., Park, S.-Y., Szarka, L. A., & Camilleri, M. (2019) · American Journal of Gastroenterology · doi:10.1038/s41395-018-0234-1 · Cited by 65
Self-citationEffects of hemin on heme oxygenase-1, gastric emptying, and symptoms in diabetic gastroparesis
Bharucha, A. E., Daley, S. L., Low, P. A., Gibbons, S. J., Choi, K. M., Camilleri, M., Saw, J. J., Farrugia, G., & Zinsmeister, A. R. (2016) · Neurogastroenterology & Motility · doi:10.1111/nmo.12874 · Cited by 37 · cited 1×
“Unfortunately, the pharmacokinetics of the hemin in that trial were insufficient to conclusively test whether countering oxidative stress can restore normal ENS function and gastric emptying (Bharucha et al., 2016).”
BackgroundSelf-citation
Cited by
Tzeis, S., Gerstenfeld, E. P., Kalman, J., Saad, E. B., Sepehri Shamloo, A., Andrade, J. G., Barbhaiya, C. R., Baykaner, T., Boveda, S., Calkins, H., et al. (2024) · Europace · doi:10.1093/europace/euae043 · Cited by 634
Tzeis, S., Gerstenfeld, E. P., Kalman, J., Saad, E. B., Shamloo, A. S., Andrade, J. G., Barbhaiya, C. R., Baykaner, T., Boveda, S., Calkins, H., et al. (2024) · Heart Rhythm · doi:10.1016/j.hrthm.2024.03.017 · Cited by 298
Camilleri, M., & Sanders, K. M. (2022) · Gastroenterology · doi:10.1053/j.gastro.2021.10.028 · Cited by 151
Self-citationJalleh, R. J., Jones, K. L., Rayner, C. K., Marathe, C. S., Wu, T., & Horowitz, M. (2022) · Diabetologia · doi:10.1007/s00125-022-05796-1 · Cited by 87
“are also concerns regarding potential drug-interactions and a reduction in long-term efficacy due to tachyphylaxis [73].”
BackgroundInfluentialEnteric neuropathy in diabetes: Implications for gastrointestinal function
Abdalla, M. M. I. (2024) · World Journal of Gastroenterology · doi:10.3748/wjg.v30.i22.2852 · Cited by 45
Metadata
- Authors
- Camilleri, M., & Atieh, J.
- Venue
- Frontiers in Pharmacology
- Publisher
- Frontiers Media SA
- Published
- 2021-08-24
- Volume
- 12
- Pages
- 711500-711500
- ISSN
- 1663-9812 (ISSN-L)
- OpenAlex
- W3193618424
- Cited by
- 104
- References
- 13
- FWCI
- 13.13
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.